logo
Plus   Neg
Share
Email
Comment

Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients

Novartis (NVS) announced new data showing almost 90% of chronic spontaneous urticaria or CSU patients who responded well to initial Xolair (omalizumab) treatment regained symptom control within 12 weeks of Xolair retreatment following a treatment interruption, based on Weekly Urticaria Activity Score (UAS7) criteria.

The OPTIMA Phase IIIb data re-confirmed that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled. Xolair is a targeted therapy that binds to immunoglobulin E or IgE.

CSU is a distressing skin condition that appears spontaneously and causes persistent hives and/or painful deeper swelling of the skin for 6 weeks or more. As per international treatment guidelines, the goal of treatment for CSU is the complete elimination of symptoms.

Novartis noted that Xolair can reduce or eliminate symptoms for CSU patients who have not successfully controlled their symptoms with H1 antihistamine (H1-antagonists) treatment.

Xolair is the first and only approved therapy for CSU patients who show an inadequate response to H1 antihistamines.

The company noted that findings were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland.

Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis, said, "CSU can have a severe impact on quality of life. Its unpredictable nature, combined with the fact that some physicians mistakenly dismiss it as a trivial condition, can mean patients do not get adequate treatment with effective and long-term symptoms control. If for some reason treatment has been interrupted, these data give patients and physicians confidence that it's possible to regain effective symptom control with Xolair."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Tech giants Amazon.com, YouTube and Twitter as well as Verizon Communications are exploring bids for digital streaming rights to the National Football League or NFL's Thursday Night Football package, according to media reports. The NFL is likely to strike a multi-year deal for the digital streaming rights. However, the television audience for the NFL has declined for two consecutive years. Wynn Resorts Ltd. said Friday that former Chief Executive Officer Steve Wynn is not entitled to any severance payment of other compensation from the company. Wynn resigned last week as CEO and Chairman of the board following allegations of sexual misconduct. In a regulatory filing, Wynn Resorts said it entered into a separation agreement between Steve Wynn, and Wynn Resorts Holdings LLC. Beverages giant Coca-Cola Company on Friday reported a net loss for the fourth quarter, reflecting a one-time charge related to the U.S. tax reform and a double-digit decline in revenues. However, adjusted earnings per share matched analysts' expectations, while revenues beat their estimates. The company's shares are rising more than 2 percent in pre-market activity.
comments powered by Disqus
Follow RTT